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Abstract
Background—Children with sickle cell disease (SCD) are at increased risk of illness and death 
from invasive pneumococcal disease (IPD). The introduction in 2000 of the 7-valent 
pneumococcal conjugate vaccine (PCV7) and penicillin prophylaxis for children with SCD has 
greatly reduced the incidence of IPD in this population. However, a recent report suggested an 
increase in cases of IPD in children with SCD.
Methods—Using data from Active Bacterial Core surveillance (ABCs), we analyzed trends in 
hospitalizations, mortality, and serotype among children with SCD compared with other children. 
We used neonatal screening data to estimate SCD population denominators for each ABCs site.
Results—From 1998–2009, 3,069 cases of IPD occurred among African-American children less 
than 18 years of age in the ABCs catchment area. Of these, 127 (4.1%) had SCD identified by 
medical chart review and 185 (6.0%) had one or more IPD risk factors, excluding SCD. Rates of 
IPD among children with SCD declined by 53% (1,118 versus 530 per 100,000) while the overall 
rates among African-American children declined by 74% (54 to 14 per 100,000). For all time 
periods, children with SCD and IPD were more likely to be hospitalized (84%–92% versus 31%–
56%) and more likely to die (6%–17% versus 1%–2%) than children with no risk factors.
Conclusions—While the rate of IPD in children with SCD has dropped dramatically since 
PCV7 introduction, the rate of IPD in children with SCD remains higher than that of the general 
population of African-American children, pointing to the need for more effective prevention 
efforts to prevent IPD in children with SCD.
Introduction
Children with sickle cell disease (SCD) have higher rates of invasive bacterial infections, 
including bacteremia, pneumonia, and meningitis (1, 2). In particular, since children with 
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SCD often become functionally asplenic, they are at increased risk of infections caused by 
encapsulated bacteria such as Streptococcus pneumoniae (3). Before licensure of the seven-
valent pneumococcal conjugate vaccine (PCV7) in the United States in 2000, children with 
SCD were recommended to receive penicillin prophylaxis until 5 years of age and to receive 
one dose of the 23-valent pneumococcal polysaccharide vaccine (PPV23) at 2 years of age 
(4, 5). Despite these interventions, rates of invasive pneumococcal disease (IPD) in children 
with SCD remained significantly higher than in healthy children (4, 6, 7) and pneumococcal 
infection was a leading infectious cause of death in children with SCD (8).
In pre-licensure trials of PCV7, the vaccine was found, unlike PPV23, to be immunogenic in 
children <2 years old (6, 9). Therefore, in addition to receiving PCV7 as part of the routine 
schedule at 2, 4, 6, and 12–15 months of age, PCV7 was specifically recommended for 
children 24–59 months of age with SCD (7). In the 11 years since PCV7’s introduction, 
cases of IPD caused by the seven serotypes included in the vaccine have all but disappeared 
in the general pediatric population as well as in children with SCD (2, 10, 11). However, a 
recent report suggests a possible increase in the rate of IPD in children with SCD, 
particularly in the number of cases caused by non-PCV7 serotypes(12). At the same time, 
rates of non-PCV7 serotypes, especially types 19A and 7F, have increased significantly in 
healthy children (10, 13, 14). We sought to estimate the rate of IPD in children with SCD 
before and after the introduction of PCV7 and to compare cases of IPD among children with 
and without SCD.
Materials and Methods
Cases of IPD in African-American children under 18 years of age were identified through 
the Active Bacterial Core surveillance (ABCs) system with Streptococcus pneumoniae 
isolated from a normally sterile site (e.g., blood, cerebrospinal fluid, etc.) from 1998–2009. 
ABCs is an active population- and laboratory-based surveillance system which is a 
collaborative effort between the Centers for Disease Control and Prevention (CDC), state 
and local health departments, and academic institutions(15). As of 2009, ABCs included 1.4 
million African-American children less than 18 years of age (16). ABCs collects 
demographic, hospitalization, and outcome information, and relevant underlying conditions 
(including SCD) for all cases via medical chart review. Additionally, all available isolates 
are tested for antimicrobial resistance by the Clinical Laboratory and Standards Institute 
broth microdilution procedure and serotype using latex agglutination and confirmation by 
Quellung reaction (17). PCV7 serotypes include the seven serotypes included in the vaccine 
(4, 6B, 9V, 14, 18C, 19F, and 23F), as well as serotype 6A, which is cross-reactive with the 
serotype 6B antigen in PCV7 and thus declined after PCV7 introduction(18). Therefore, 
despite the inclusion of serotype 6A only in the newer version of the conjugate vaccine 
introduced in 2010 (PCV13), we considered serotype 6A to be a “PCV7” serotype. The 
other five serotypes unique to PCV13 (1, 3, 5, 7F, 19A) were considered PCV5 serotypes.
Cases were grouped into three time periods: 1) Pre-PCV7 (1998–99); 2) Early-PCV7 (2000–
2004); and 3) Late-PCV7 (2005–2009). These time periods were chosen based on 
availability of data and to allow analysis of key demographics, risk factors, and outcomes 
both immediately after PCV7’s introduction and in the years immediately before PCV13 
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was introduced (a potential baseline for future analyses). Analyses compared children with 
SCD (regardless of the presence of other underlying conditions), children without SCD who 
had one or more other risk factor for IPD (e.g., diabetes, HIV/AIDS, congenital heart 
disease, cancer, etc.), and children without these risk factors. Comparisons were made using 
chi-squared, Fisher’s exact, and t-tests and differences were considered statistically 
significant at p < .05. Analyses were conducted using SAS, version 9.2 (SAS Institute Inc., 
Cary, NC).
Prevalence of SCD within the ABCs catchment area was estimated using a method similar 
to that of Hassel(19) (see Figure, Supplemental Digital Content 1). Briefly, incidence of 
SCD in African-American newborns in each of the ABCs states was estimated by dividing 
the total number of African-American newborn births(20) in each state with genotypes SS, 
SC, and Sβ Thalassemia, as reported in the National Newborn Screening Information 
System(21) or by the state’s department of health via personal communication, in 2005, 
2006, and 2007 by the total number of African-American newborn births(20) in each state 
over those year. When state-specific and/or race-specific data for newborns with SCD were 
not available, a national incidence rate was used. SCD newborn incidence estimates were 
then applied to birth cohorts(20) that would be under 18 during the relevant year of ABCs 
surveillance (e.g. 1981–1998 for surveillance year 1998); this calculation provided an 
estimate of the number of newborns with SCD in each birth cohort. The total number of 
SCD patients during each ABCs calendar year was estimated by adjusting each birth cohort 
population by estimated mortality rates published by Quinn et al(22) and summing over all 
birth cohorts included in that surveillance year. The pediatric prevalence of SCD in the 
ABCs states during each year was estimated by dividing the estimated number of SCD 
patients by the total number of African-American children less than 18 at that year (23). 
These prevalence estimates were then applied to the ABCs catchment area for that state in 
order to estimate the number of SCD patients covered in the catchment area. Rates of IPD in 
African-American children with SCD were estimated by dividing the number of cases of 
IPD in children with SCD reported to ABCs in a given time period by the estimated number 
of children with SCD in the ABCs catchment area during that time period.
Results
A total of 3,069 cases of IPD occurred in African-American children less than 18 years of 
age in the catchment area during 1998–2009 (Table 1). Of these, 127 (4.1%) had SCD 
identified during their medical chart review. An additional 185 (6.0%) had one or more IPD 
risk factors other than SCD, such as leukemia, immunosuppressive therapy, or diabetes.
Demographics
Children with SCD and those with other risk factors were significantly older at the time of 
culture than children without IPD risk factors (median range across time periods: 45–63 
months for SCD; 42–76 months for children with other risk factors; 15–20 months for 
children without risk factors), consistent with the observation that rates of IPD in the general 
population decline markedly after age 5 years(10). There was a significant (p<0.0001) 
upward trend in age at the time of culture from 1998 to 2009 among children without risk 
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factors, but no significant trend in either children with SCD or children with other 
underlying conditions.
Clinical Presentation and Outcomes
Children with SCD were significantly more likely than either of the other groups to have 
pneumococcal meningitis in the early-PCV7 period; however, this outcome did not differ 
significantly in the other time periods. Children with SCD and those with other risk factors 
were significantly more likely to be hospitalized during their IPD episode in all time periods 
compared with children without IPD risk factors, and children with SCD were more likely to 
die from IPD than children without SCD. However, children with SCD had shorter average 
length of hospitalizations than children without SCD after vaccine introduction.
Trends in IPD
Rates of IPD among children with SCD less than 18 years of age declined by 53% (Figure 
1), from an average of 1,118 cases per 100,000 children (CI: 814/100,000–1,1537/100,000) 
before PCV7 introduction to an average of 530 cases per 100,000 children (CI: 
424/100,000–664/100,000) after vaccine introduction. The rate of IPD among children with 
SCD has remained relatively stable since vaccine introduction, with rates ranging from a 
low of 290 cases per 100,000 children in 2004 to a high of 510 cases per 100,000 children in 
2006. Rates of IPD among children with SCD <18 year of age remain higher than the overall 
rate among African-American children. The incidence rate ratio comparing the rate of IPD 
among children with SCD to the overall rate among African-American children was 5 (4–7) 
in the pre-PCV7 period, 29 (23–37) in the early-PCV7 period, and 44 (35–56) in the late-
PCV7 period. The decline in incidence of IPD among children with SCD post vaccine 
introduction but remaining disparity compared to children without SCD was observed in 
children younger and older than 5 years of age (Table 2).
Significant declines in PCV7-type IPD, as well as increases in PCV5-type disease were seen 
amongst all three groups (Table 3). PCV5 serotypes are those primarily responsible for the 
phenomenon known as ‘serotype replacement’ in the general population(24). During the 
pre-PCV7 period, the distribution of serotypes causing disease in children with and without 
SCD was similar, with the vast majority of cases caused by one of the PCV7 serotypes. In 
the late-PCV7 period, however, children with SCD had fewer cases of IPD caused by the 
PCV5 types (SCD 24%, other risk factors 41%, no risk factors 57%). In contrast, 45% of 
IPD in children with SCD was caused by one of four serotypes: 6C (19% of cases), 15A 
(12% of cases), and 15B/C (14% of cases). These same four serotypes accounted for only 
11% of cases among children with other underlying conditions and only 9% of cases among 
children without these conditions.
In the pre-PCV7 period, IPD isolates obtained from children with SCD were significantly 
more likely than the other two groups to be nonsusceptible to one or more classes of 
antibiotics (77% of isolates in children with SCD vs. 44% in the other-risk-factors group and 
45% in the no-risk-factors group). Among SCD cases, 77% were nonsusceptible in the pre-
PCV7 period compared to 45% in the late-PCV7 period.
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Our estimates indicate the rate of IPD in children with SCD has dropped 53% since vaccine 
introduction. This trend has been previously reported(2, 4, 11, 25) and explains the 
observations of reduced mortality(8) and hospitalizations(11) due to IPD in children with 
SCD that have also been previously reported. The results of this study support the fact that 
the introduction of PCV7 has effectively reduced the burden of IPD in children with SCD.
While the rate of IPD in children with SCD has declined significantly since PCV7 
introduction, we found the rate is still dramatically higher than the overall rate in African-
American children. Our analyses also indicate children with SCD still have significantly 
higher mortality due to IPD than children with other underlying conditions and healthy 
children, implying children with SCD are still disproportionately affected by IPD. This is 
likely due to the inherently increased susceptibility to disease among children with SCD(26).
Because children with SCD are at increased risk for infection, the American Academy of 
Pediatrics (AAP) recommends all children with sickle cell disease receive penicillin 
prophylaxis at least until their fifth birthday(27). Furthermore, the AAP recommends timely 
administration of the pneumococcal conjugate and 23-valent pneumococcal polysaccharide 
vaccines (PPV23), defined as administration of the conjugate vaccine at 2, 4, 6 and 12–15 
months of age and administration of the 23-valent vaccine in high-risk children at the 
earliest opportunity to expand serotype coverage(28). These prevention strategies have 
served to drastically reduce the rate of IPD in children with SCD, as shown by this and other 
analyses (11). However, the increased incidence rate of IPD among children with SCD 
compared with the overall population of African-American children remains, pointing to a 
need for further examination of prevention strategies. Importantly, the Advisory Committee 
on Immunization Practices recently (29) voted to recommend routine administration of one 
dose of PCV13 to children 6 through 18 years of age with immunocompromising conditions, 
including SCD, who have not previously received PCV13, regardless of whether they have 
previously received PCV7or PPV23. Future evaluations of the impact of this new 
recommendation are needed. Conjugate vaccines with broader serotype coverage or vaccines 
that target a broader diversity of pneumococci are urgently needed.
McCavit et al describe a trend of increasing mean age of onset of IPD in children with SCD 
in a large sample of hospitalized pediatric patients before and after PCV7 introduction(11). 
Although not statistically significant, we also report this trend. In their report, McCavit et al 
suggest reconsideration of cessation of penicillin prophylaxis at age 5 and immunization 
schedules for children with SCD. Our results indicate more research in this area is 
warranted.
In children with SCD we found a significant increase over time in IPD caused by serotypes 
unique to PCV13, a phenomenon known as serotype replacement. A similar increase has 
been seen in healthy children since the introduction of PCV7. Of concern, while serotypes 
accounting for 60% of IPD among children with no risk factors in the late-PCV7 era are 
covered by PCV13, only 26% of IPD in children with SCD is represented by PCV13 
serotypes. The remaining disease (74%) in that time period was due to serotypes not 
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included in PCV13, leaving children with SCD more likely to be unprotected by the 
conjugate vaccine. Of note, the most common non-PCV13 serotype causing IPD in children 
with SCD in the late-PCV7 era was serotype 6C, which may be cross-reactive with the 
serotype 6A antigen in PCV13 (30). If PCV13 does provide cross-protection against 
serotype 6C, an additional 19% of IPD in children with SCD may be preventable.
Our study has certain limitations. Because the number of children living with SCD was not 
known, we estimated rates of SCD in the ABCs catchment area to define the SCD 
population. These estimates were derived from data reported to the National Newborn 
Screening Information System. Reporting of these data has been shown to be variable for 
some states. These estimates also do not account for immigration and emigration into and 
out of the catchment area. However, because we applied the same method to all ABCs sites 
and all years, any under- or over-estimation of the rate of SCD would not affect the overall 
trends observed. Also, we did not estimate PCV7 or PPV23 vaccine coverage in children 
with SCD. Thus, we were unable to determine if the disparity in rates of IPD among 
African-American children with and without SCD is due to differences in vaccine coverage 
and/or vaccine effectiveness. We were also unable to determine if the disparity in rates of 
IPD among African-American children with and without SCD is due to ascertainment 
differences. It has been reported that total blood cultures drawn in children with no IPD risk 
factors has decreased since vaccine introduction(31). However, treatment guidelines(32) 
published by the National Heart, Lung, and Blood Institute recommend febrile patients with 
SCD be evaluated rapidly and intensively for possible Streptococcus pneumoniae infection, 
making it more likely cases of IPD would be detected in children with SCD compared to 
children without SCD.
Conclusion
This report demonstrates the effectiveness of the PCV7 vaccine to dramatically reduce the 
rate of IPD in children with SCD. However, our analyses show children with SCD are still at 
much greater risk of IPD infection than healthy children and are more likely to die as a result 
of infection. This indicates better prevention strategies are warranted to reduce the overall 
morbidity and mortality due to IPD in children with SCD.
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Rates of IPD in children under 18 with SCD compared to overall rate of IPD in African-
American children under 18 in ABCs (1998–2009)
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